Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
By T. Lindner, A. Loktev, A. Altmann, F. Giesel, C. Kratochwil, J. Debus, D. Jäger, W. Mier, U. Haberkorn. Journal of Nuclear Medicine, 2018
815 citations recorded by the source corpus.
Subfields: Cancer Research, Cellular and Molecular Neuroscience, Oncology
View Paper: https://www.semanticscholar.org/paper/ae6434798e4a0a33d854517c07f7c4d26a973a7b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- C. Kratochwil
- F. Giesel
- A. Loktev
- P. Flechsig
- T. Lindner
- W. Mier
- A. Altmann
- Labidi Abderrahim
Citations in the corpus
- A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts (2018, background): “This may be done by modification of the binding moiety or the linker or by use of different chelators (24).”
- 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers (2018, background): “2) (5), would still be required to refine the potential of FAPI-targeting radionuclide therapy, for example, with 153Sm or 90Y.”
- 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer (2019, background): “It should be mentioned that unspecific fibrosis may also cause issues for 68Ga-FAPI PET; however, because of the inherent difference in normal activated fibroblasts and cancerassociated fibroblasts (4,5), this possibility FIGURE 3.”